Eno

ENO India is an Indian company that specializes in producing antacid powder. The company's headquarters is located in Mumbai, Maharashtra. ENO India is a subsidiary of GlaxoSmithKline (GSK), a multinational pharmaceutical company based in the United Kingdom. ENO India has a rich history dating back to 1839 when James Crossley Eno invented the original fruit salt formula. He then started the production of Eno's Fruit Salt in England. The popularity of the product grew rapidly, and it was introduced to India in 1899. Since then, ENO has become a household name and has established itself as a leading antacid brand in the country. The main product offered by ENO India is ENO Fruit Salt, a fast-acting antacid powder used for the relief of indigestion, flatulence, and acidity. It is available in various flavors and is widely used by consumers in India. On a global scale, ENO India operates as a subsidiary of GSK. GSK is a well-known player in the pharmaceutical industry and has a presence in over 150 countries. The company has numerous subsidiaries, joint ventures, and partnerships worldwide, but specific information about any noteworthy subsidiaries or partnerships related to ENO India is not readily available. ENO India has established a strong market position in India, particularly in the antacid segment. It enjoys a high level of brand recognition and consumer trust. The company competes with other well-known antacid brands in the Indian market, such as Digene and Pudin Hara. In terms of sales, ENO India's exact market share and global sales figures are not publicly disclosed. However, it is widely recognized that ENO is one of the top-selling antacid brands in India. There have been no major recent events, achievements, or changes in ENO India's brand strategy or product lineup that significantly impact its growth. As of the latest available information, ENO India continues to operate as a key player in the antacid market in India. However, for the most up-to-date and accurate information about the company's current status and latest updates, further research or consultation with official sources is recommended.